AntoXa

Life-saving biodefense solutions

You are here: Home / News

News

Welcome to AntoXa Corporation’s newsroom.

For media inquiries, please contact:

Stacey Curry Gunn
Director of Communications
stacey.curry.gunn@antoxacorp.com
519.827.1131

See below for links to the latest AntoXa news.

 

AntoXa Corporation granted Defence R&D Canada license for novel, plant-made anti-ricin antibody

GUELPH, Ont., Canada, April 16, 2018— AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide. The licensing agreement follows work AntoXa and the J.C ...
Continue reading ...
/ News Releases, Products

Study shows antibody’s efficacy against ricin

AntoXa is working with Defence Research & Development Canada (DRDC) to develop and produce a plant-made antibody, PhD9, to protect against ricin exposure, a program that has received more than $400,000 (CDN) from the Government of Canada since 2014. Ricin is a naturally occurring protein from Ricinus communis. It is ...
Continue reading ...
/ News Releases

Studies target immune response to Ebola infection

A University of New Mexico scientist is partnering with AntoXa’s parent company, PlantForm Corporation, to advance research aimed at improving understanding of Ebola virus and improving existing vaccines by inducing more effective immune responses to infection. The project employs PlantForm’s tobacco-plant-based vivoXPRESS® biopharmaceutical manufacturing system. The aim is to express ...
Continue reading ...
/ News Releases

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.